Page 2 - Torrent Pharma

Strong profit growth keeps brokerages positive on Torrent Pharma

Led by an 18% y-o-y growth in the domestic formulations segment, which accounts for over half its overall revenues, the company posted 16% growth at a consolidated level

Torrent Pharma Q2 net profit rises 24% to Rs 386 cr on strong demand

Consolidated net profit was Rs 386 crore for the quarter ended Sept. 30, compared with Rs 312 crore a year earlier

Sensex sinks 826 pts, Nifty ends below 19,300; SmallCap index slides 4%

Stock market live on October 23, 2023: At 7:15 am, the Gift Nifty futures were nearly flat at 19,520 levels

Govt may divest 7% stake in Hudco, Torrent Pharma's promoters get exemption

Sebi has granted open offer exem­ption to the promoters of Torrent Pharma and Torrent Power

Trusts linked to Torrent Power, others from open offer conditions exempted

Regulator Sebi on Tuesday exempted four family trusts linked to promoters from making open offers to the shareholders of three companies -- Torrent Power, Torrent Pharmaceuticals and Gujarat Lease Financing -- following their proposed indirect share acquisition in these firms. The orders came after four Mehta Family Trusts filed applications with the regulator in July 2023, and sought exemption from certain provisions of takeover regulations. In order to facilitate succession planning, Sudhir Uttamlal Mehta and Samir Uttamlal Mehta created four trusts to streamline the family's shareholding in Torrent Investments Private Limited (TIPL). Under the proposed acquisitions, four acquirer trusts intended to acquire interest in the target companies -- Torrent Power, Torrent Pharmaceuticals and Gujarat Lease Financing -- indirectly from TIPL, one of the promoters of these firms, according to three separate orders by the Securities and Exchange Board of India (Sebi). The acquirer trusts pla

Pharma result preview: US stable, India muted in the second quarter

Hospital occupancy rates rise 200-400 bps, while diagnostic sector sees seasonal benefits

Torrent in talks with Apollo to borrow up to $1 bn for Cipla bid: Reports

Torrent has also been in talks with CVC Capital Partners and Bain Capital who might become equity partners in a consortium and contribute as much as a combined $1.5 billion to the deal, sources said

Torrent pharma in advance talks with CVC Capital to buyout Cipla promoters

Torrent had reached out to several private equity (PE) funds, including Bain Capital to secure the necessary funds to buyout the promoter family of Cipla

Cipla on the block: Who's a better fit and what it means for shareholders?

As per IIFL Securities, Cipla with a dominating market share of 7% and 23% in acute therapies like respiratory and anti-infectives, respectively, would strengthen Torrent's position in these

Stocks to Watch today, Sep 11: Adani Grp, HDFC Bank, RIL, Sonata, IRB Infra

Stocks to watch on September 11, 2023: Balrampur, Delta Corp, India Cements, Manappuram, PNB and SAIL among nine stocks in F&O ban on Monday.

Stocks to Watch: Vishnu Prakash, Hero Moto, Cipla, Escorts, Oil, IEX, M&M

Stocks to watch on September 5, 2023: Vishnu Prakash R Punglia will debut on the bourses today. The issue price is Rs 99 and the stock may list with up to 60 per cent premium

Torrent Pharma gears up to buyout Cipla promoters, approach PE funding

Torrent Pharma might pay a total of Rs 60,000 crore (around $7.2 billion) for a 59.47 per cent stake in the 88-year-old pharmaceutical company

Stocks to Watch: Torrent Pharma, Cipla, TVS Supply Chain, Titan, AdaniTotal

Stocks to Watch on August 23, 2023: Torrent Pharma has joined the race to buy out Cipla's promoter stake held by the Hamied family, reported The Economic Times

Stocks to Watch today, Aug 08: Airtel, Max Health, GIC Housing, Sobha, BEML

Stocks to watch on August 08, 2023: Adani Ports, Coal India, Hindalco, Jet Airways, Oil India and Utkarsh SFB are few of the notable companies to announce June quarter earnings on Tuesday.

Torrent Pharma's net profit rises 7% at Rs 378 crore in April-June quarter

Torrent Pharma on Monday reported a 7 per cent increase in its profit after tax to Rs 378 crore for the June quarter. The company had reported a profit after tax (PAT) of Rs 354 crore in the year-ago quarter. Revenue for the first quarter of the current fiscal rose to Rs 2,591 crore as against Rs 2,347 crore in the year-ago period, Torrent Pharma said in a statement. The drug firm said its domestic revenue grew 14.5 per cent year-on-year to Rs 1,426 crore during the quarter. The company said its revenue also went up in Brazil and Germany by 3 per cent and 21 per cent, respectively. Revenue in the US market, however, declined by 2 per cent to Rs 293 crore, it added. Torrent Pharma shares ended 0.49 per cent down at Rs 2,051.50 apiece on the BSE.

Torrent Pharma surges 8%, hits record high post March quarter results

Torrent's branded generics business India continues to perform well with focus on curatio acquisition and focus on power brands besides consumer business foray.

Stocks to watch: Adani Ports, NMDC, HDFC Life, Apollo Hospitals, PTC Inds

Stocks to watch on May 31, 2023: From Adani Ports to Sun Pharma, here are top stocks to watch in Wednesday's trading session

Torrent Power posts Rs 484 cr Q4 net profit in, income grows to 6,133.70 cr

Torrent Power on Monday reported Rs 483.93 crore consolidated net profit in the March 2023 quarter, mainly on the back of higher revenues. The company had reported a consolidated net loss of Rs 487.37 crore in the quarter ended March 2022, a BSE filing showed. Its total income rose to 6,133.70 crore in the quarter from Rs 3,840.59 crore in the year-ago period. The consolidated net profit in the fiscal 2022-23 rose to Rs 2,164.67 crore from Rs 458.70 crore in the previous fiscal. Its total income in the fiscal increased to Rs 26,075.97 crore against Rs 14,492.65 crore in 2021-22. The board has recommended a final dividend of Rs 4 per equity share for 2022-23. This final dividend along with an interim dividend of Rs 22.00 per equity share works out to a total dividend of Rs 26.00 per equity share (including Rs 13.00 per equity share as a special dividend) for the 2022-23. The final dividend, if declared by the members at the ensuing AGM will be paid to the members, subject to deduc

Results preview: India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels

Torrent Pharmaceuticals forays into OTC segment with calcium supplement

Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.